- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06022029
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (ON-5001)
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This Phase 1, multi-center trial will consist of three parts: monotherapy dose escalation; combination therapy dose finding; and combination therapy dose expansion exploring two doses in specific tumor indication(s). Each dosing cycle of ONM-501 will be 21 days. ONM 501 will be administered as intratumoral injections once per week for three weeks (on Days 1, 8, and 15), followed by three weeks without ONM-501 administration. The monotherapy dose escalation will utilize an accelerated titration method.
The combination agent will be administered according to standard protocol, once every three weeks. This phase will evaluate ONM-501 in combination with approved immune checkpoint inhibitor (ICI) cemiplimab. Enrollment in this phase will follow a "Rolling 6" or 6+0 methodology - up to 6 patients will be enrolled in a staggered format; dose escalation of ONM-501 will be permitted.
Once the recommended doses for expansion (RDEs) are determined for ONM-501 + ICI combination or ONM-501 monotherapy, the expansion phase of this study will be initiated. The expansion phase will enroll patients in one to three indication-specific expansion cohorts.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Trials@OncoNanoMed.com
- Phone Number: (682) 285-1411
- Email: trials@onconanomed.com
Study Locations
-
-
Florida
-
Tamarac, Florida, United States, 33321
- Recruiting
- BRCR Global
-
Contact:
- Isabela Vazquez
- Phone Number: 114 541-447-0614
- Email: Isabelav@brcrglobal.com
-
Principal Investigator:
- Chintan Gandhi, MD
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University
-
Contact:
- Allison Reynolds
- Email: osuccclinicaltrials@osumc.edu
-
Principal Investigator:
- Joal Beane, MD
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- Recruiting
- UPMC Hillman Cancer Center
-
Principal Investigator:
- Liza Villaruz, MD
-
Contact:
- Barb Stadterman
- Phone Number: 412-647-5554
- Email: stadtermanbm@upmc.edu
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- Allegheny Health Network
-
Principal Investigator:
- Patrick Wagner, MD
-
Contact:
- Shelly A Evans, MBA, BS, RN
- Phone Number: 724-612-2931
- Email: Shelly.evans@ahn.org
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- University of Texas Southwestern Medical Center
-
Contact:
- Heather McArthur, MD
- Phone Number: 833-722-6237
- Email: canceranswerline@utsouthwestern.edu
-
Principal Investigator:
- Heather McArthur
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Principal Investigator:
- Sarina A. Piha-Paul, MD
-
Contact:
- Hebah Elbahy
- Phone Number: 832-294-7238
- Email: HMElbahy@mdanderson.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to understand and willingness to sign written informed consent before performance of any study procedures
- Age ≥ 18 years
- Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumor therapy, and for which no alternative standard therapy exists.
- Participants must have a minimum of one injectable and measurable lesion.
- Participants with prior Hepatitis B or C are eligible if they have adequate liver function
- Participants with human immunodeficiency virus (HIV) are eligible if on established HAART for a minimum of 4 weeks prior to enrollment, have an HIV viral load <400 copies/mL, and have CD4+ T-cell (CD4+) counts ≥ 350 cells/uL
- Adequate bone marrow function:
- Adequate liver function
Exclusion Criteria: Patients will be excluded from this study if they meet any of the following criteria (Part 1a and Part 1b).
- Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy.
- Major surgery within 4 weeks before the first dose of study drug.
- Brain metastases that are untreated or in the posterior fossa or involve the meninges. Participants with stable or previously treated progressing brain metastases (except in the posterior fossa or involving the meninges) may be permitted in a case-by-case basis at the Sponsor's discretion.
- Prolongation of corrected QT (QTc) interval to >470 millisecond (ms) for males and females when electrolytes balance is normal.
- Females who are breastfeeding or pregnant at screening or baseline
- Females of childbearing potential that refuse to use a highly effective method of contraception.
- Has uncontrolled or poorly controlled hypertension as defined by a sustained BP > 9. Has received prior investigational therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter.
- Has had any major cardiovascular event within 6 months prior to study drug 10. Has known hypersensitivity to any component in the formulation of ONM-501
- Has an active infection requiring systemic treatment
- Is participating in another therapeutic clinical trial
Additional Exclusion Criteria for ONM-501 in Combination with cemiplimab (Part 1b)
- Has known hypersensitivity to any component in the formulation of cemiplimab
- Has any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (>10 mg daily prednisone equivalent)
- Has a condition requiring systemic treatment with corticosteroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1a: Monotherapy Dose Escalation
ONM-501 will be administered as intratumoral injections once per week for three weeks, followed by three weeks without ONM-501 administration.
Each dosing cycle will be 21 days.
|
Intratumoral injection
|
Experimental: Part 1b: ONM-501 in Combination with cemiplimab
ONM-501 will be administered as intratumoral injections once per week for three weeks followed by three weeks without ONM-501 administration.
Each dosing cycle will be 21 days.
The combination agent will be administered according to standard protocol, once every three weeks.
|
Intratumoral injection
Intravenous administration of 350 mg
Other Names:
|
Experimental: Part 2: RDE ONM-501 in Combination with cemiplimab in indication-specific expansion cohorts
Once the recommended doses for expansion (RDEs) are determined for ONM-501 + ICI combination or ONM-501 monotherapy, the expansion phase of the study will be initiated.
The expansion phase will enroll patients in one to three indication-specific expansion cohorts.
|
Intratumoral injection
Intravenous administration of 350 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Escalation and Expansion Phases: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity
Time Frame: Up to approximately 24 months
|
AE incidence will be coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology.
AE severity will be graded according to NCI CTCAE version 5.0 or later.
Grade 1 scales as Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 scales as Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living [ADL]); Grade 3 scales as Severe (severe or medically significant but not immediately life threatening hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4 scales as Life-threatening consequences, urgent intervention indicated, and Grade 5 scales as Death related to Adverse Event (AE)
|
Up to approximately 24 months
|
Dose Escalation and Expansion Phases: Number of Participants with Dose-Limiting Toxicities (DLTs)
Time Frame: Up to approximately 24 months
|
DLT will be defined as the occurrence of any of the following events in the first 28 days of treatment in the dose escalation cohorts in Part 1 of the study or in the first 28 days of treatment for the first 6 patients at any dose in Part 1b (DLT observation periods).
Any adverse event resulting in a dose hold or delay of ≥ 28 days will be considered a DLT.
Toxicity will be evaluated according to NCI CTCAE version 5.0.
|
Up to approximately 24 months
|
Dose Escalation and Expansion Phases: Number of Participants Reporting One or More Treatment Emergent Serious Adverse Event (SAEs)
Time Frame: Up to approximately 24 months
|
AE incidence will be coded using Medical Dictionary for Regulatory Activities (MedDRA) terminology.
AE severity will be graded according to NCI CTCAE version 5.0 or later.
|
Up to approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expansion Phase Only: Overall Survival (OS)
Time Frame: Up to approximately 24 months
|
OS is defined as the time from the date of first dose administration to the date of death.
|
Up to approximately 24 months
|
Dose Escalation and Expansion Phases: Cmax
Time Frame: Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
Cmax is defined as the Maximum Observed Plasma Concentration for ONM-501
|
Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
Dose Escalation and Expansion Phases: t1/2z
Time Frame: Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
t1/2z is defined as the Terminal Disposition Phase Half-life for ONM-501
|
Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
Dose Escalation and Expansion Phases: Tmax
Time Frame: Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
Tmax is defined as the Time to Reach the Maximum Plasma Concentration (Cmax) for ONM-501
|
Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
Dose Escalation and Expansion Phases: AUCt
Time Frame: Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
AUCt is defined as the Area Under the Concentration-time Curve from Time 0 to Time t for ONM-501
|
Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
Dose Escalation and Expansion Phases: AUCinf
Time Frame: Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
AUCinf is defined as the Area Under the Concentration-time Curve from Time 0 to Infinity for ONM-501
|
Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
Dose Escalation and Expansion Phases: CL/F
Time Frame: Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
CL/F is defined as the apparent clearance of ONM-501 (CL/F), where F is the fraction of the dose absorbed.
|
Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
Dose Escalation and Expansion Phases: Vz/F
Time Frame: Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
Vz/F is defined as the apparent volume of distribution of ONM-501 (CL/F), where F is the fraction of the dose absorbed.
|
Dose Escalation and Expansion Phases: Cycle 1 Day 1 and Cycle 1 Day 8 (each cycle is 21 days): predose and at multiple timepoints (up to 24 hours).
|
Expansion Phase Only: Objective Response Rate (ORR)
Time Frame: Up to approximately 24 months
|
Objective response will be defined as a best response of CR or PR. The objective response rate (ORR) will be calculated as the proportion of patients in the Efficacy Analysis Set who achieve an objective response. ORR will be assessed based on Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Characterize the plasma pharmacokinetics (PK) of IT ONM-501 as monotherapy and in combination with cemiplimab Evaluate additional measures of clinical benefit including: Duration of Response (DOR), Progression Free Survival (PFS) by RECIST and Overall Survival |
Up to approximately 24 months
|
Expansion Phase Only: Duration of Response (DOR)
Time Frame: Up to approximately 24 months
|
DOR analyses will be conducted for those patients in the Efficacy Analysis Set who achieve an objective response and is defined as the time from first objective status assessment of CR or PR until documentation of objective disease progression or death from any cause.
Patients who do not progress and do not die will be censored on the date of last adequate tumor assessment.
If no further adequate post-treatment tumor assessments were obtained for a patient, DOR will be censored at the date of the objective response (i.e., zero duration).
DOR will be assessed based on RECIST v1.1.
|
Up to approximately 24 months
|
Expansion Phase Only: Progression-Free Survival (PFS)
Time Frame: Up to approximately 24 months
|
PFS is defined as the time from administration of the first dose of ONM-501 until documentation of objective disease progression or death from any cause. Patients who do not progress and do not die will be censored on the date of last adequate tumor assessment. If no adequate post treatment tumor assessments were obtained for a patient, PFS will be censored at Day 1 (i.e., zero duration). The PFS analysis will be conducted using the Safety Analysis Set. Assess the biological effects of IT ONM-501 demonstrated by changes in immune cells, immune cell markers, serum cytokines (such as TNF-⍺, IFN-⍺, IFN-β, and others consistent with activation of the cGAS-STING pathway) and gene expression patterns |
Up to approximately 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Breast Cancer
- metastases
- immunotherapy
- DLBCL
- Solid tumors
- Lymphoma
- NHL
- Skin Cancer
- bladder cancer
- Melanoma
- Triple Negative
- TNBC
- HNSCC
- BRCA2
- FL
- BRCA1
- cervical cancer
- mTNBC
- anti-PD-L1
- ICI
- STING
- anti-PD-1 antibody
- uveal
- cemiplimab
- ONM-501
- Intra-tumoral
- Libtayo
- Mantle Zone lymphoma
- stimulator of interferon genes
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Disease Attributes
- Breast Diseases
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Lymphoma, B-Cell
- Carcinoma, Squamous Cell
- Breast Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Neoplasms
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Uterine Cervical Neoplasms
- Carcinoma in Situ
- Carcinoma
- Recurrence
- Lymphoma, Non-Hodgkin
- Urinary Bladder Neoplasms
- Lymphoma, Mantle-Cell
- Melanoma
- Squamous Cell Carcinoma of Head and Neck
- Skin Neoplasms
- Triple Negative Breast Neoplasms
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Cemiplimab
Other Study ID Numbers
- ON-5001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Non-Hodgkin
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Clinical Trials on ONM-501
-
OncoNano Medicine, Inc.CompletedBreast Cancer | Colorectal Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial CarcinomaUnited States
-
OncoNano Medicine, Inc.Completed
-
OncoNano Medicine, Inc.Completed
-
Chong Kun Dang PharmaceuticalCompletedType 2 Diabetes MellitusKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type 2Korea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType 2 DiabetesKorea, Republic of
-
Bellicum PharmaceuticalsActive, not recruitingLymphoma | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Acute Myelogenous LeukemiaUnited States
-
Otsuka Pharmaceutical Co., Ltd.CompletedAcute Myeloid LeukemiaJapan
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Bellicum PharmaceuticalsWithdrawnRecurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic... and other conditionsUnited States
-
Dermavant Sciences GmbHCompletedAtopic DermatitisCanada, United States